Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Medipal, JCR Kick Off Japan PI/II of MPS IIIB Therapy
Medipal Holdings and JCR Pharmaceuticals said on December 3 that the first patient has been dosed in a Japan PI/II trial for JR-446, an investigational drug for mucopolysaccharidosis type IIIB (MPS IIIB), a lysosome disease also known as Sanfilippo syndrome…
To read the full story
Related Article
- Medipal/JCR’s MPS IIIB Drug Now in Line to Enter Clinic
July 2, 2024
- Medipal/JCR to Pair Up for Mucopolysaccharidosis Type IIIB Drug
September 29, 2023
BUSINESS
- Sawai Prevails in ALS Drug Contract Appeal against Neugen
July 3, 2026
- Insilico, Takeda Ink AI Drug Discovery Deal Worth Up to US$600 Million
July 3, 2026
- Otsuka’s Voyxact Shows Two-Year Kidney Benefit in PIII IgAN Trial
July 3, 2026
- PeptiDream, NCC Start FIH Study of CLDN18.2 Radiopharmaceutical
July 3, 2026
- PeptiDream Poaches 3 EVPs to Bolster Global Expansion
July 3, 2026
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…